Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Medscape Oncology to Make a Significant Impact at ASCO 2024

    May 31, 2024 |  

    - PMLiVE

    ASCO is one of the biggest conferences of the year for Medscape Oncology, and the team is ready to make an impact in Chicago. They’ll be manning booth #26030, where they’ll be chatting with conference attendees about all things Medscape, oncology education, and patient centricity. The Medscape booth will also house a full recording studio where faculty members will gather to film future education programs.

    The Medscape team will also host five educational symposia led by oncology experts that will help share the latest data and information, and provide learners with the opportunity to network and ask questions. The symposia will cover topics such as glioma care, relapsed diffuse large B-cell lymphoma, metastatic colorectal cancer, NSCLC management, and relapsed follicular lymphoma. Medscape members will be able to apply for credit for the events.

    As part of their commitment to publication, Medscape will also present three scientific posters online at ASCO.org on the impact of CME and micro CE/CME. 

    For more information on oncology education at Medscape, please contact Chris Carey (ccarey@medscape.net) 

    This content was provided by Medscape Education

    Company Details

    Medscape Logo

    Medscape Education

    Email
    Website

     Latest Content from  Medscape Education 

    What Does Net Promoter Score Offer in the Evaluation of Continuing Medical Education?

    Net promoter Score (NPS) has been used in many fields, such as software, clinical care, and websites, as a measure of customer satisfaction since 2003. With a single question, NPS...

    DIGITAL HEALTH IN PRACTICE AND OVERCOMING DIGITAL FATIGUE

    During this year’s Reuters event, Pharma 2022, WebMD CMO, Dr John Whyte discussed the ways in which digital health is growing, and the importance of educating clinicians in the right...

    ESMO’s New Focus on Cancer Prevention

    During ESMO 2022 in Paris, John Whyte, chief medical officer at WebMD was joined by Fabrice André, MD, PhD, Chair of the scientific committee at the European Society for Medical Oncology (ESMO),...

    ESMO Patient Centricity – Highlights from Steve Clark

    During #ESMO22 we brought together a panel of world-renowned experts, including WebMD CMO John Whyte, Professor Nadia Harbeck, MD, PhD, Lesley Fallowfield DBE, and Steve Clark, patient advocate and campaigns ambassador, Cancer Research UK (CRUK),...

    ESMO Patient Centricity Highlights from Dr. Whyte

    During #ESMO22 we brought together a panel of world-renowned experts, including WebMD CMO John Whyte, Professor Nadia Harbeck, MD, PhD, Lesley Fallowfield DBE, and Steve Clark, patient advocate and campaigns ambassador, Cancer Research UK (CRUK), volunteer...

    Closing The Gaps in Patient-Centricity in Cancer Care

    Highlights from the Medscape Education full panel discussion during this year's #ESMO22.

    Full Panel Discussion: Closing The Gaps In Patient-Centricity

    On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

    Medscape Education: Key Takeaways from Tapas and Trends

    This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...

    Medscape Education #ESC Tapas and Trends Full Panel Discussion

    This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...

    A Look at What’s Next After ESC

    This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...